Y-mAbs Therapeutics Inc
NASDAQ:YMAB
Y-mAbs Therapeutics Inc
NASDAQ:YMAB
Price:
12.87 USD
-5.44%
Market Closed
Updated:
May 10, 2024
Y-mAbs Therapeutics Inc
Operating Expenses
|
Y-mAbs Therapeutics Inc
Operating Expenses Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Operating Expenses Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Y-mAbs Therapeutics Inc
NASDAQ:YMAB
|
Operating Expenses
-$94.6m
|
CAGR 3-Years
12%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Operating Expenses
-$19.5B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-9%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Operating Expenses
-$12.1B
|
CAGR 3-Years
9%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-11%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Operating Expenses
-$12.5B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Operating Expenses
-$4.8B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-14%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Operating Expenses
-$7.3B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-19%
|
See Also
What is Y-mAbs Therapeutics Inc's Operating Expenses?
Operating Expenses
-94.6m
USD
-94.6m
USD
Based on the financial report for Dec 31, 2023, Y-mAbs Therapeutics Inc's Operating Expenses amounts to -94.6m USD.
What is Y-mAbs Therapeutics Inc's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
-17%
-17%
Over the last year, the Operating Expenses growth was 38%. The average annual Operating Expenses growth rates for Y-mAbs Therapeutics Inc have been 12% over the past three years , -17% over the past five years .
You don't have any saved screeners yet
